KR100712571B1 - 코카인 중독증의 치료용 약제를 제조하기 위한플루마제닐의 용도 - Google Patents

코카인 중독증의 치료용 약제를 제조하기 위한플루마제닐의 용도 Download PDF

Info

Publication number
KR100712571B1
KR100712571B1 KR1020037010718A KR20037010718A KR100712571B1 KR 100712571 B1 KR100712571 B1 KR 100712571B1 KR 1020037010718 A KR1020037010718 A KR 1020037010718A KR 20037010718 A KR20037010718 A KR 20037010718A KR 100712571 B1 KR100712571 B1 KR 100712571B1
Authority
KR
South Korea
Prior art keywords
delete delete
cocaine
treatment
flumazenyl
benzodiazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037010718A
Other languages
English (en)
Korean (ko)
Other versions
KR20040010592A (ko
Inventor
후안호세 레가르다아바네즈
Original Assignee
하이디엄, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하이디엄, 인크. filed Critical 하이디엄, 인크.
Publication of KR20040010592A publication Critical patent/KR20040010592A/ko
Application granted granted Critical
Publication of KR100712571B1 publication Critical patent/KR100712571B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
KR1020037010718A 2001-02-15 2002-02-08 코카인 중독증의 치료용 약제를 제조하기 위한플루마제닐의 용도 Expired - Fee Related KR100712571B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200100342 2001-02-15
ESP200100342 2001-02-15
PCT/ES2002/000061 WO2002064213A1 (es) 2001-02-15 2002-02-08 Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la dependencia de cocaina

Publications (2)

Publication Number Publication Date
KR20040010592A KR20040010592A (ko) 2004-01-31
KR100712571B1 true KR100712571B1 (ko) 2007-05-02

Family

ID=8496743

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037010718A Expired - Fee Related KR100712571B1 (ko) 2001-02-15 2002-02-08 코카인 중독증의 치료용 약제를 제조하기 위한플루마제닐의 용도

Country Status (20)

Country Link
US (2) US7186711B2 (https=)
EP (1) EP1378267B1 (https=)
JP (2) JP4272885B2 (https=)
KR (1) KR100712571B1 (https=)
CN (1) CN1327843C (https=)
AT (1) ATE363923T1 (https=)
AU (1) AU2002231811B2 (https=)
BR (1) BR0207866A (https=)
CA (1) CA2436511C (https=)
CY (1) CY1106845T1 (https=)
DE (1) DE60220512T2 (https=)
DK (1) DK1378267T3 (https=)
ES (1) ES2287255T3 (https=)
IL (1) IL157144A0 (https=)
MX (1) MXPA03007281A (https=)
NZ (1) NZ528164A (https=)
PT (1) PT1378267E (https=)
RU (1) RU2322985C2 (https=)
UA (1) UA79586C2 (https=)
WO (1) WO2002064213A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US7855196B2 (en) 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
ES2289935B1 (es) * 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
US9396280B2 (en) * 2008-06-23 2016-07-19 Microsoft Technology Licensing, Llc Command driven web site browsing
ES2702848T3 (es) 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
US9308616B2 (en) 2013-01-21 2016-04-12 Innovative Finishes LLC Refurbished component, electronic device including the same, and method of refurbishing a component of an electronic device
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
CN107115359A (zh) * 2016-02-24 2017-09-01 郑恩哲 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
GB9225859D0 (en) * 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9420010D0 (en) 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
CA2436511C (en) 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1020037010718 - 686376

Also Published As

Publication number Publication date
HK1061817A1 (en) 2004-10-08
EP1378267B1 (en) 2007-06-06
PT1378267E (pt) 2007-09-11
NZ528164A (en) 2006-03-31
ATE363923T1 (de) 2007-06-15
US20070142364A1 (en) 2007-06-21
DE60220512T2 (de) 2008-02-07
WO2002064213A1 (es) 2002-08-22
DK1378267T3 (da) 2007-10-08
JP2008201799A (ja) 2008-09-04
MXPA03007281A (es) 2005-01-25
DE60220512D1 (de) 2007-07-19
JP4272885B2 (ja) 2009-06-03
AU2002231811B2 (en) 2006-02-16
KR20040010592A (ko) 2004-01-31
CN1491125A (zh) 2004-04-21
CA2436511A1 (en) 2002-08-22
RU2322985C2 (ru) 2008-04-27
US20060122219A1 (en) 2006-06-08
IL157144A0 (en) 2004-02-08
RU2003127718A (ru) 2005-01-27
US7186711B2 (en) 2007-03-06
EP1378267A1 (en) 2004-01-07
BR0207866A (pt) 2004-03-23
CN1327843C (zh) 2007-07-25
JP2004521904A (ja) 2004-07-22
CY1106845T1 (el) 2012-05-23
UA79586C2 (en) 2007-07-10
ES2287255T3 (es) 2007-12-16
CA2436511C (en) 2009-08-04

Similar Documents

Publication Publication Date Title
JP2008201799A (ja) コカイン依存症治療用薬剤
JP2008201796A (ja) アルコール依存症治療用の薬剤
JPH11505547A (ja) ナルトレキソン及び関連化合物を用いる禁煙処置
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
HRP20020189A2 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
JP2004519461A5 (https=)
JP2004521904A5 (https=)
KR20080004615A (ko) 알코올 및/또는 흥분성 물질 남용의 치료를 위한 선택적클로라이드 채널 조절제의 용도
AU2006200922A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
HK1061817B (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
AU2006246490B2 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
HK1061661B (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20110318

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120424

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120424